Why microfracture alone often isn't enough

A focal cartilage lesion on the hip joint surface presents a specific clinical challenge: the damaged area will not repair itself. Unlike bone, articular cartilage — the smooth white tissue lining the femoral head and acetabulum — contains no blood vessels and very few cells capable of regeneration. Once a full-thickness defect develops, the joint has no reliable mechanism for self-restoration without surgical help.

Microfracture was for many years the standard first response to contained focal defects, and many patients seen at Lincolnshire Hip will have encountered it during their workup. By perforating the subchondral bone beneath the lesion, surgeons release bone-marrow-derived cells and growth factors that partially fill the void. The repair tissue that forms, however, is predominantly fibrocartilage — a mechanically inferior substitute that lacks the load-bearing architecture of the original hyaline cartilage. Published series report fewer than 60% of treated joints surviving beyond three years after microfracture, with a mean time to failure of around four years. Repeated microfracture also risks disrupting the subchondral bone plate, which can narrow the options available for more advanced repair later.

AMIC — Autologous Matrix-Induced Chondrogenesis — was developed specifically to address this durability ceiling. Introduced by Behrens et al., it builds on microfracture rather than discarding it: the marrow stimulation step remains, but a collagen scaffold is applied immediately over the perforated zone to transform a fragile repair clot into a more organised, guided healing environment.

How AMIC works: the scaffold's three roles

The procedure itself unfolds in two closely linked steps, performed during the same operation. First, the surgeon removes any unstable or damaged cartilage until the defect has clean, vertical walls — a stable border that will hold the repair in place. The subchondral bone beneath is then perforated using a fine awl or drill (the microfracture step), creating a series of small channels that release bone-marrow stem cells and growth factors into the defect. Next, a bilayer collagen membrane — typically Chondro-Gide®, made from porcine collagen types I and III — is cut to match the precise shape of the defect using a sterile template, then fixed over the perforated zone with sutures or fibrin glue.

The scaffold does three distinct things once in position, and understanding each helps explain why AMIC tends to produce more durable results than microfracture on its own.

Trap. When marrow is released through the perforations, it forms a blood clot rich in bone-marrow stem cells. Without a covering, that clot is vulnerable — joint fluid and early motion can displace it before it has chance to organise. The membrane acts as a biological lid, keeping the stem-cell-rich clot contained within the defect during the early healing window.

Guide. The collagen matrix provides a three-dimensional framework that influences what those stem cells become. Rather than differentiating into fibrocartilage — the mechanically weaker tissue that microfracture typically produces — the cells within the scaffold are directed toward a chondrocyte-like phenotype, producing repair tissue that is more structurally organised and hyaline-like in character. It is worth being precise here: the aim is tissue that resembles hyaline cartilage more closely than fibrocartilage does, not a perfect regeneration of the original.

Protect. Early mechanical disruption is a key reason repair tissue fails. The membrane shields the immature tissue as it consolidates, reducing the risk that normal joint forces undermine the repair before it has adequately matured.

Because all of this happens in a single operative sitting, AMIC avoids the two-stage process required by autologous chondrocyte implantation (ACI) or MACI, where a separate cell-harvest procedure must take place weeks before implantation. For patients and clinical teams weighing their options, that distinction — one operation rather than two — carries practical weight.

Applying AMIC in the hip joint: technical realities

Hip anatomy makes this procedure meaningfully different from its knee counterpart, and that distinction matters when patients are weighing options.

The hip is a deep ball-and-socket joint: the femoral head sits within the acetabular cup, creating two curved, congruent articular surfaces rather than the flatter geometry of a knee condyle. Focal cartilage damage here most commonly arises from femoroacetabular impingement (FAI) — where abnormal bony morphology causes repetitive articular contact — though acute trauma, repetitive loading, and developmental structural anomalies affecting the acetabular rim or femoral head can all produce the same pattern of focal chondral injury in younger, active adults.

Those curved surfaces add a layer of technical complexity. The collagen scaffold must be sized and fixed so that it conforms precisely to the concave or convex geometry of the defect — any mismatch risks edge-lifting or inadequate contact during the early healing period. Where arthroscopic access allows adequate visualisation and instrument reach, this remains the preferred route for appropriately sized and sited lesions. For larger defects or those sited posteriorly on the femoral head or acetabulum, open surgical dislocation of the hip provides the exposure needed for accurate preparation and scaffold placement.

Because FAI and labral pathology co-exist with the cartilage lesion in a significant proportion of cases, the bony and soft-tissue corrections are typically addressed in the same operative sitting — treating the underlying cause and the cartilage damage together rather than in sequence.

The depth of the hip joint and the precision demanded by its geometry mean that the operating team's specific experience with hip arthroscopy is a meaningful variable in how well preparation and fixation can be achieved.

What the clinical evidence shows

The strongest available evidence comes from the AMIC Registry reported by Gille et al., which followed 57 patients with a mean age of 37.3 years and a mean defect size of 3.4 cm². At both 1-year and 2-year follow-up, patients recorded significant reductions in VAS pain scores (p < 0.001) and significant gains in functional outcome measures. That sustained improvement across two years of follow-up places AMIC clearly above what standalone microfracture typically delivers over the same interval.

Two further studies help frame where AMIC sits relative to other options. An RCT by Fossum et al. (41 patients) comparing AMIC directly against autologous chondrocyte implantation found comparable outcomes at equivalent time points — relevant because ACI is the established benchmark for mid-to-large chondral defects. A retrospective series by Schiavoni Panni et al. reported AMIC to be effective in full-thickness defects larger than 2 cm² out to 7-year follow-up in 21 patients, which offers a longer durability signal than most scaffold studies provide.

Post-procedure MRI typically confirms tissue filling within the treated defect. Some patients do show scaffold hypertrophy or subchondral bone abnormalities on imaging, which is why follow-up scanning forms part of standard monitoring after the procedure.

A necessary qualification on the evidence base

The data above — including the Gille Registry and the Fossum RCT — derive from knee studies. Published AMIC series focused specifically on the hip joint are fewer and generally shorter in follow-up. The biological mechanism and scaffold principles are considered transferable, but hip-specific long-term outcome data beyond two to five years remain sparse. This does not make hip AMIC an experimental procedure, but it does mean that patient selection and realistic expectations need to be guided by a thorough consultant assessment rather than direct extrapolation from knee figures.

Who is a suitable candidate for hip AMIC

Suitability for hip AMIC depends on three converging factors: the depth of the cartilage damage, the size of the defect, and the overall condition of the joint.

Depth of damage. AMIC is indicated for ICRS Grade 3 or Grade 4 lesions — in plain terms, damage that extends more than halfway through the cartilage layer (Grade 3) or penetrates all the way to the subchondral bone beneath it (Grade 4). Shallower, partial-thickness lesions do not require this level of intervention.

Defect size. This is the most decisive single variable. For lesions under approximately 2 cm², microfracture alone or osteochondral autograft transfer may deliver adequate results. For defects of 3 cm² or larger, scaffold-augmented techniques such as AMIC show superior long-term durability compared to marrow stimulation alone. Patients who have an MRI report quoting a defect measurement can use that figure as an initial reference point, though formal operative assessment remains the definitive measure.

Joint condition. The strongest candidates are younger, active adults with a single, contained focal chondral lesion in an otherwise structurally sound hip. Diffuse osteoarthritis, multiple lesions across both joint surfaces, or significant subchondral bone loss move a patient outside the scope of cartilage restoration. For those individuals, an honest discussion about the limits of joint preservation — and the point at which hip replacement becomes the more appropriate pathway — is more constructive than pursuing a restorative procedure.

One further candidacy requirement: where femoroacetabular impingement or another structural driver is present, correcting it forms part of the same procedure. A repair undertaken without addressing the underlying mechanical cause is substantially less likely to hold.

Recovery after hip AMIC and next steps

Recovering from hip AMIC takes time, and the honest starting point is that published rehabilitation protocols specific to this procedure in the hip joint are not well represented in the literature. Clinical teams therefore draw on experience from hip MACI recovery and knee AMIC programmes, tailoring the pathway to each patient's defect size, fixation approach, and any concurrent procedures carried out in the same operation.

The broad structural pattern is consistent: an initial period of protected weight-bearing to allow the scaffold and the developing repair tissue to mature without mechanical disruption, followed by graduated loading as the tissue consolidates, and a progressive return to full activity over several months. How long each phase lasts is determined by the operating team in response to the individual clinical picture, not by a fixed schedule.

MRI at six to twelve months is standard practice to assess scaffold integration and defect fill. As noted in the evidence section, some patients show scaffold hypertrophy or subchondral changes on follow-up imaging; identifying these early allows the clinical team to adjust rehabilitation accordingly.

For patients who would like to explore whether hip AMIC or another cartilage restoration approach is appropriate for them, Lincolnshire Hip accepts patients without referral. Professor Paul Y. F. Lee leads the hip cartilage pathway at Sleaford and Grantham, and a consultant assessment is the right starting point for any individualised discussion.